Drug Approval | August 23, 2024
Wanbury receives EIR from FDA for Patalganga facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
The emergence of new infections in India is a growing concern
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This two-day program was attended by 40 doctors & paramedical staff
Subscribe To Our Newsletter & Stay Updated
